Is there still a gender gap in medical research?

The episode examines the historical exclusion of women from NIH-funded medical trials until 1993, the flawed 'two-bucket' model of sex in research, and how oversimplification leads to misdiagnosis and unequal treatment. It highlights the Ambien dosing case, where women metabolize the drug more slowly, prompting an FDA dose reduction in 2013. Experts argue for more precise definitions of sex in research and caution against attributing differences solely to biology when social factors like gender bias in pain assessment play a role.

It reveals how deeply embedded assumptions about sex in medicine distort research and care, offering a critical lens on both biological and social determinants of health outcomes.

1. 01Women were excluded from NIH-funded trials until 1993 due to thalidomide fallout and assumptions about hormonal variability.
2. 02The 'two-bucket' model (male/female) in medical research overlooks significant overlap and individual variation, leading to misdiagnosis—e.g., heart attack symptoms in women and men.
3. 03Sex-based drug dosing, like with Ambien, reveals both progress and pitfalls: while biologically informed, it risks oversimplification without addressing broader systemic biases in care.